Targeting the HLA-DRβ1-Arg74 pocket with compounds like Cepharanthine offers a personalized medicine approach for autoimmune thyroid diseases (AITDs), as treatment would be tailored specifically to individuals carrying the HLA-DRβ1-Arg74 risk variant. The gene discussed is HLA-DRB1; the disease is autoimmune thyroid disease.